Challenges in the treatment of BRAF K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinib

被引：0

作者：

Nishiyama, Akihiro ^{[1
]}

Sato, Shigeki ^{[1
]}

Sakaguchi, Hiroyuki ^{[1
]}

Kotani, Hiroshi ^{[1
]}

Yamashita, Kaname ^{[1
]}

Ohtsubo, Koushiro ^{[1
]}

Nanjo, Shigeki ^{[2
]}

Yano, Seiji ^{[2
]}

Mizuguchi, Keishi ^{[3
]}

Ikeda, Hiroko ^{[3
]}

Takeuchi, Shinji ^{[1
]}

机构：

[1] Kanazawa Univ Hosp, Dept Med Oncol, Kanazawa, Japan

[2] Kanazawa Univ Hosp, Dept Resp Med, Kanazawa, Japan

[3] Kanazawa Univ Hosp, Dept Diagnost Pathol, Kanazawa, Japan

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

BRAF K601E mutation; lung carcinoma; dabrafenib; trametinib; resistance to targeted therapy; liquid biopsy; INHIBITORS;

D O I：

10.3389/fonc.2024.1374594

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We report a case of limited effectiveness of dabrafenib and trametinib in a 59-year-old man with poorly differentiated lung carcinoma and a rare BRAF K601E mutation. The patient, unresponsive to chemotherapy and immunotherapy, received these targeted agents as second-line treatment. Despite a notable initial response, tumor regression lasted only 52 days. A subsequent liquid biopsy revealed additional alterations (BRAF amplification, KIT amplification, TP53 S241F), indicating a complex resistance mechanism. This case underscores the challenges in treating BRAF K601E-mutant lung carcinoma, emphasizing the need for advanced molecular diagnostics, personalized approaches, and further research into more effective therapies for unique genetic profiles.

引用

页数：5

共 12 条

[1] An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib [J].

Abravanel, Daniel L. ;

Nishino, Mizuki ;

Sholl, Lynette M. ;

Ambrogio, Chiara ;

Awad, Mark M. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :E131-E133

[2] Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling [J].

Adamopoulos, Christos ;

Ahmed, Tamer A. ;

Tucker, Maxwell R. ;

Ung, Peter M. U. ;

Xiao, Min ;

Karoulia, Zoi ;

Amabile, Angelo ;

Wu, Xuewei ;

Aaronson, Stuart A. ;

Ang, Celina ;

Rebecca, Vito W. ;

Brown, Brian D. ;

Schlessinger, Avner ;

Herlyn, Meenhard ;

Wang, Qi ;

Shaw, David E. ;

Poulikakos, Poulikos, I .

CANCER DISCOVERY, 2021, 11 (07) :1716-1735

[3] BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation [J].

Corcoran, Ryan B. ;

Dias-Santagata, Dora ;

Bergethon, Kristin ;

Iafrate, A. John ;

Settleman, Jeffrey ;

Engelman, Jeffrey A. .

SCIENCE SIGNALING, 2010, 3 (149)

[4] Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer [J].

Facchinetti, Francesco ;

Lacroix, Ludovic ;

Mezquita, Laura ;

Scoazec, Jean-Yves ;

Loriot, Yohann ;

Tselikas, Lambros ;

Gazzah, Anas ;

Rouleau, Etienne ;

Adam, Julien ;

Michiels, Stefan ;

Massard, Christophe ;

Andre, Fabrice ;

Olaussen, Ken A. ;

Vassal, Gilles ;

Howarth, Karen ;

Besse, Benjamin ;

Soria, Jean-Charles ;

Friboulet, Luc ;

Planchard, David .

EUROPEAN JOURNAL OF CANCER, 2020, 132 :211-223

[5]

Karoulia Z, 2016, CANCER CELL, V30, P485, DOI 10.1016/j.ccell.2016.06.024

[6] Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer [J].

Kron, A. ;

Alidousty, C. ;

Scheffler, M. ;

Merkelbach-Bruse, S. ;

Seidel, D. ;

Riedel, R. ;

Ihle, M. A. ;

Michels, S. ;

Nogova, L. ;

Fassunke, J. ;

Heydt, C. ;

Kron, F. ;

Ueckeroth, F. ;

Serke, M. ;

Krueger, S. ;

Grohe, C. ;

Koschel, D. ;

Benedikter, J. ;

Kaminsky, B. ;

Schaaf, B. ;

Braess, J. ;

Sebastian, M. ;

Kambartel, K. -O. ;

Thomas, R. ;

Zander, T. ;

Schultheis, A. M. ;

Buettner, R. ;

Wolf, J. .

ANNALS OF ONCOLOGY, 2018, 29 (10) :2068-2075

[7] Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies [J].

Lovly, Christine M. ;

Shaw, Alice T. .

CLINICAL CANCER RESEARCH, 2014, 20 (09) :2249-2256

[8] Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations [J].

Menzer, Christian ;

Menzies, Alexander M. ;

Carlino, Matteo S. ;

Reijers, Irene ;

Groen, Emma J. ;

Eigentler, Thomas ;

de Groot, Jan Willem B. ;

van der Veldt, Astrid A. M. ;

Johnson, Douglas B. ;

Meiss, Frank ;

Schlaak, Max ;

Schilling, Bastian ;

Westgeest, Hans M. ;

Gutzmer, Ralf ;

Pfoehler, Claudia ;

Meier, Friedegund ;

Zimmer, Lisa ;

Suijkerbuijk, Karijn P. M. ;

Haalck, Thomas ;

Thoms, Kai-Martin ;

Herbschleb, Karin ;

Leichsenring, Jonas ;

Menzer, Alexander ;

Kopp-Schneider, Annette ;

Long, Georgina V. ;

Kefford, Richard ;

Enk, Alexander ;

Blank, Christian U. ;

Hassel, Jessica C. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (33) :3142-+

[9] Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database [J].

Owsley, Jeff ;

Stein, Matthew K. ;

Porter, Jason ;

In, Gino K. ;

Salem, Mohamed ;

O'Day, Steven ;

Elliott, Andrew ;

Poorman, Kelsey ;

Gibney, Geoffrey ;

VanderWalde, Ari .

EXPERIMENTAL BIOLOGY AND MEDICINE, 2021, 246 (01) :31-39

[10] Dabrafenib plus trametinib in BRAF K601E-mutant melanoma [J].

Rogiers, A. ;

Thomas, D. ;

Vander Borght, S. ;

van den Oord, J. J. ;

Bechter, O. ;

Dewaele, M. ;

Rambow, F. ;

Marine, J. -C. ;

Wolter, P. .

BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (02) :421-422

← 1 2 →